Sibylla Biotech
Pre-clinicalBy exploiting this new paradigm that we named “Pharmacological Protein Inactivation by Folding Intermediates Targeting” (PPI-FIT), Sibylla can identify and develop small molecules acting on targets involved in different types of diseases. Indeed, PPI-FIT is applicable to any therapeutic area.
Founded
2016
Focus
Small Molecules
About
By exploiting this new paradigm that we named “Pharmacological Protein Inactivation by Folding Intermediates Targeting” (PPI-FIT), Sibylla can identify and develop small molecules acting on targets involved in different types of diseases. Indeed, PPI-FIT is applicable to any therapeutic area.
Funding History
2Total raised: $12.5M
Series A$10MNovartis Venture FundJun 15, 2021
Seed$2.5MIndaco Venture PartnersJun 15, 2018
Company Info
TypePrivate
Founded2016
LocationPerugia, Italy
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
AAVantgarde Bio
Pre-clinical · Milan
AB ANALITICA
Pre-clinical · Padua
BetaGlue Therapeutics
Phase 1 · Milan
Adienne Pharma and Biotech
Pre-clinical · Milan
Advaxia Biologics
Pre-clinical · Milan
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile